UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 364

Sortiert nach

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

Current oncology (Toronto), 2011-06, Vol.18 (3), p.126-138

Hirsh, V

2011

Volltextzugriff (PDF)

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Annals of oncology, 2010-09, Vol.21 (9), p.1804-1809

2010

Volltextzugriff (PDF)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Annals of oncology, 2017-02, Vol.28 (2), p.270-277

2017

Volltextzugriff (PDF)

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Annals of oncology, 2016-11, Vol.27 (11), p.2103-2110

2016

Volltextzugriff (PDF)

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC

Cancer treatment reviews, 2018-04, Vol.65, p.65-77

2018

Volltextzugriff (PDF)

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer

Current oncology (Toronto), 2019-02, Vol.26 (1), p.37-42

2019

Volltextzugriff (PDF)

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

Current oncology (Toronto), 2014-12, Vol.21 (6), p.329-336

2014

Volltextzugriff (PDF)

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Annals of oncology, 2015-08, Vol.26 (8), p.1741-1748

2015

Volltextzugriff (PDF)

Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

Annals of oncology, 2004-01, Vol.15 (1), p.19-27

2004

Volltextzugriff (PDF)

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-02, Vol.24 (2), p.314-321

2013

Volltextzugriff (PDF)

The changing landscape of thoracic malignancies

Current oncology (Toronto), 2018-06, Vol.25 (Suppl 1), p.S5-6

2018

Volltextzugriff (PDF)

Future of personalized medicine in non-small-cell lung cancer

Current oncology (Toronto), 2012-06, Vol.19 (Suppl 1), p.S86-86

Hirsh, V

2012

Volltextzugriff (PDF)

Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer

Current oncology (Toronto), 2018-06, Vol.25 (Suppl 1), p.S9-17

2018

Volltextzugriff (PDF)

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-09, Vol.24 (9), p.2390-2396

2013

Volltextzugriff (PDF)

Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach

Current oncology (Toronto), 2010-04, Vol.17 (2), p.13-23

Hirsh, V

2010

Volltextzugriff (PDF)

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Current oncology (Toronto), 2019-02, Vol.26 (1), p.e81-93

2019

Volltextzugriff (PDF)

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

European journal of cancer (1990), 2014-03, Vol.50 (4), p.706-712

2014

Volltextzugriff (PDF)

Randomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0g/dL

Annals of oncology, 2018-10, Vol.29, p.viii499-viii500

2018

Volltextzugriff (PDF)

MS 20.01 When is a Treatment Considered Futile?

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1713-S1714

Hirsh, V.

2017

Volltextzugriff (PDF)

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

British journal of cancer, 2015-06, Vol.113 (1), p.20-29

2015

Volltextzugriff (PDF)

Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S43-S43

2014

Volltextzugriff (PDF)

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (5), p.S21-S21

2014

Volltextzugriff (PDF)

Small Cell Lung Cancer Limited Disease (LSCLC): Are Long Treatments With Higher Doses Really Needed?

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.E421-E421

2015

Volltextzugriff (PDF)

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

OncoTargets and therapy, 2017-01, Vol.10, p.2513-2526

Hirsh, Vera

2017

Volltextzugriff (PDF)

EP1.14-28 A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1043-S1043

2019

Volltextzugriff (PDF)

1 – 25 von 364

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(337)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(157)
Life Sciences & Biomedicine
(145)
Humans
(118)
Male
(78)
Female
(77)
Middle Aged
(56)
Oncology
(56)
Adult
(50)
Biological And Medical Sciences
(48)
Medical Sciences
(43)
Aged
(41)
Lung Neoplasms - Drug Therapy
(29)
Hematology, Oncology And Palliative Medicine
(27)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(25)
Pharmacology. Drug Treatments
(25)
Lung Neoplasms - Pathology
(22)
Treatment Outcome
(22)
General & Internal Medicine
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Mutation
(16)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(40)
Annals Of Oncology
(37)
Journal Of Thoracic Oncology
(24)
Current Oncology
(16)
Chest
(11)
International Journal Of Radiation Oncology, Biology, Physics
(11)
Lung Cancer
(10)
European Journal Of Cancer
(9)
Circulation
(8)
The Lancet
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC

Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer

The changing landscape of thoracic malignancies

Future of personalized medicine in non-small-cell lung cancer

Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer

Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

Randomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0g/dL

MS 20.01 When is a Treatment Considered Futile?

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer Limited Disease (LSCLC): Are Long Treatments With Higher Doses Really Needed?

New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

EP1.14-28 A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern